RxDoctor Payments Data

Joshua Hess, NP

Nurse Practitioner · Kingsport, TNNPI 1487140562

Payments from drug & device makers

$1,887in general payments, 2019–2025

Across 89 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$272
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$248
  • Teva Pharmaceuticals USA, Inc.$238
  • Otsuka America Pharmaceutical, Inc.$237
  • E.r. Squibb & Sons, L.L.C.$205
  • Alkermes, Inc.$205
  • plus $484 from 7 others

What the payments were for

  • Food & beverage$1,84098%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,887 in reported general payments places this provider in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$7,743
Medicare patients
39
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate15$54,474
RexultiBrexpiprazole25$39,570
VraylarCariprazine Hcl20$27,761
AristadaAripiprazole Lauroxil11$17,769
Aripiprazole60$10,355
Asenapine Maleate11$2,748
Atomoxetine Hcl16$2,728
Hydroxyzine Hcl105$1,997
Buspirone Hcl139$1,838
Lurasidone Hcl26$1,584
Duloxetine Hcl61$1,056
Trazodone Hcl101$860
Quetiapine Fumarate89$829
Risperidone62$749
Sertraline Hcl78$706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$165$54,47415 claims
Otsuka America Pharmaceutical, Inc.Rexulti$237$39,57025 claims
AbbVieVraylar$14$27,76120 claims
Alkermes, Inc.Aristada$205$17,76911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →